IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Key program areas
IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we’re doing to help solve them.

► HIV
In 2022, 1.3 million people acquired HIV, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

• Advance the next generation of vaccines to prevent HIV acquisition by pairing sophisticated science with community-rooted research.

• Develop injectable antibodies that can prevent HIV acquisition for as long as six months with one dose.

• Partner with Africa to end HIV through ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement with the U.S. Agency for International Development through the U.S. President’s Emergency Plan for AIDS Relief.

► Tuberculosis (TB)
About one quarter of the world’s population is infected with the bacterium that causes TB; 10.6 million people are estimated to have developed TB disease in 2021, resulting in approximately 1.6 million deaths.

• Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

► Emerging Infectious Diseases
We need rapid, scalable vaccine technologies for diseases that pose public health and bio-terror threats.

• Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, and Sudan virus diseases, and COVID-19.

► Novel technologies and platforms
IAVI seeks to maximize the impact of novel technologies throughout our research portfolio so that innovations reach people in LMICs.

• Leverage our scientific, clinical, and access functions to improve access to innovative health solutions across disease areas.

► Product Development Center
IAVI’s PDC bridges the “valley of death” in biomedical innovation development to help advance promising candidates from laboratory to clinic.

• Support for 53 biologics candidates to date, out of which 25 advanced to clinical trials.

IAVI fast facts
More than 25 years of breakthrough vaccine and antibody research

~350 employees

Staff in seven countries:
India, Kenya, Netherlands, South Africa, Uganda, U.K., U.S.

Labs in La Jolla, California; Brooklyn, New York; London, U.K.; and Faridabad, India

2022 revenue: $128.1M

Revenue breakdown:
75.6% governments;
24.1% foundations and individuals;
0.3% other sources

501(c)(3) nonprofit organization
Pipeline 2023–2025

IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges. Below is the pipeline as of July 2023. For the most updated list of current candidates, go to iavi.org.

### IAVI products in development

<table>
<thead>
<tr>
<th>Candidate</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>eOD-GT8 60mer + Core-g28v2 60mer mRNA</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>eOD-GT8 60mer mRNA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BG505 SOSIP gp41, adjuvanted (AS01B)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rVSVΔG-Env-HIV</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HIV vaccine candidates**

- Phase I (IAVI G002)
- Phase I (IAVI G003)
- Phase I (IAVI W001)

**Passive immunization against HIV via bnAbs**

- Preclinical
- Phase I

**Emerging infectious diseases vaccine candidates**

- Preclinical
- Phase I

**Tuberculosis (TB) vaccine candidates**

- Preclinical
- Phase I
- Phase I (IAVI C108, C109)
- Phase I (IAVI C105)
- Phase I (IAVI C104)
- Phase I (IAVI C100)

### IAVI-supported candidates

<table>
<thead>
<tr>
<th>Candidate</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>BG505 GT11 gp140, adjuvanted</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>BG505 SOSIP gp41, adjuvanted (3M-052-AF + Alum)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA-HIV-PT123, AIDSVAX®B/E; DNA-HIV-PT123, CN54gp140, MVA CMDR,CN54gp140, TAF/FTC, TDF/FTC</td>
<td>Phase III (PrePVacc)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HIV vaccine candidates**

- Phase I (IAVI C101)
- Phase I (IAVI C107)
- Phase I (IAVI C110)
- Phase I (IAVI C108, C109)
- Phase I (IAVI C110)

**Passive immunization against HIV via bnAbs**

- Preclinical

**TB vaccine candidates**

- Phase II (A-055)

**Mini-protein for COVID-19 prophylaxis**

- Preclinical

### IAVI gratefully acknowledges the generous support provided by the following major funders:

[Image of various logos]

As of July 2023

iavi.org
info@iavi.org
Go to iavi.org/subscribe to receive our updates

Follow us: [Facebook], [Instagram], [LinkedIn], [YouTube]